US › Healthcare

Traws Pharma Inc (TRAW)

US · Healthcare · Biotechnology

$0.54+0.43%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-3.1M

EPS

$-0.16

EPS estimate

$-0.22

EPS came in at -0.16 against a street estimate of -0.22 — a beat of 27.3%.

Key statistics

Market cap

$8.7M

Forward P/E

0.0

P/B

4.84

Book value

$0.11

EPS (TTM)

$-1.83

52-week high

$3.27

52-week low

$0.43

50-day MA

$0.58

200-day MA

$1.41

Beta

1.60

Analyst view

Analysts rate Traws Pharma Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $1.00.

Shareholding

Insiders

5.33%

Institutions

40.06%

Largest institutional holders

Fund	Stake
Ally Bridge Group (NY) LLC	5.12%
Adage Capital Partners Gp LLC	4.75%
Ikarian Capital, LLC	4.41%
Orbimed Advisors LLC	3.94%
Lynx1 Capital Management, LP	3.64%
Dauntless Investment Group, LLC	2.71%
BOOTHBAY FUND MANAGEMENT, LLC	1.27%
ADAR1 Capital Management LLC	1.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Traws Pharma Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.